Hence, it was postulated that accumulation of more amyloidogenic peptides results in a cascade of events leading to increased inflammation, Tau pathology, synaptic and neuronal loss, ultimately responsible for the clinical symptoms of AD[1]. This evidence concerns the gene MAPT and Alzheimer disease.